aflibercept 2.0 mg
Sponsors
David M. Brown, M.D., Novartis Pharmaceuticals, Northern California Retina Vitreous Associates, Arshad Khanani, Retina-Vitreous Associates Medical Group
Conditions
Age Related Macular DegenerationAge-Related Macular DegenerationBranch Retinal Vein Occlusion (BRVO)Clinically Significant Diabetic Macular EdemaDiabetic Macular EdemaNeovascular Age-Related Macular Degeneration (NVAMD)
Phase 2
Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME
CompletedNCT02363621
Start: 2015-01-31End: 2017-10-31Updated: 2019-04-26
A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
RecruitingNCT07205887
Start: 2025-09-12End: 2028-06-30Target: 160Updated: 2026-09-04
Phase 4
Study for Recalcitrant Age Related Macular Degeneration
CompletedNCT01543568
Start: 2012-02-29End: 2014-10-31Updated: 2017-01-02
A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients
CompletedNCT02130024
Start: 2014-04-11End: 2017-11-15Updated: 2019-06-05
The Endurance 1 Trial
CompletedNCT02297204
Start: 2014-11-30End: 2018-03-19Updated: 2019-02-04
Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema
CompletedNCT02734407
Start: 2015-01-31End: 2017-09-27Updated: 2019-03-26